Published in Am J Hematol on August 01, 1996
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med (1994) 2.09
Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature (1987) 2.04
Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03
Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood (1992) 2.00
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep (1986) 1.91
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia. Leukemia (1997) 1.73
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol (2000) 1.53
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood (1995) 1.45
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia (2005) 1.44
Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med (1992) 1.41
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion (1996) 1.40
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol (1993) 1.38
Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood (1996) 1.33
Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant (1995) 1.32
Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant (1988) 1.27
Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol (1993) 1.23
Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis (1996) 1.20
Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood (1991) 1.17
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res (1996) 1.17
A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood (1996) 1.17
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 1.14
Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia (2002) 1.10
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood (1997) 1.10
A single-step silver enhancement method permitting rapid diagnosis of cytomegalovirus infection in formalin-fixed, paraffin-embedded tissue sections by in situ hybridization and immunoperoxidase detection. J Histochem Cytochem (1986) 1.10
Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion (1997) 1.09
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res (1999) 1.08
Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia (1995) 1.08
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res (1987) 1.08
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma (2001) 1.06
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood (1996) 1.06
Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol (1996) 1.04
Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol (1989) 1.04
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood (1995) 1.03
Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol (1994) 1.03
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer (2000) 1.03
Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol (1987) 1.02
The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant (2003) 1.01
Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene (1992) 1.01
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood (1993) 1.01
Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant (1997) 1.00
Treatment of parkinson's disease with bromocriptine. N Engl J Med (1976) 1.00
Cerebral arteritis in scleroderma. Stroke (1980) 0.98
The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant (1998) 0.98
Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites. Int J Radiat Oncol Biol Phys (1986) 0.98
Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant (1998) 0.96
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant (2004) 0.96
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol (1993) 0.96
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol (2004) 0.96
Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma (1993) 0.95
FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood (1996) 0.95
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood (1991) 0.95
Granulocytic sarcoma of the pancreas: a report of two cases and literature review. Clin Lab Haematol (1999) 0.95
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med (1998) 0.95
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood (1994) 0.94
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia (2003) 0.94
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res (1995) 0.94
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (1996) 0.93
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer (2001) 0.93
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol (1998) 0.93
Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion. Bone Marrow Transplant (1997) 0.93
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia (1995) 0.92
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer (1994) 0.91
NCCN Practice Guidelines for Acute Myelogenous Leukemia. Oncology (Williston Park) (2000) 0.91
The human calcitonin gene is located on the short arm of chromosome 11. Biochem Biophys Res Commun (1984) 0.90
Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother (1998) 0.90
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol (1994) 0.90
Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation (1999) 0.90
Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant (2001) 0.90
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia (2001) 0.90
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol (1999) 0.89
The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. Br J Clin Pharmacol (1991) 0.89
Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts. Cancer Res (1987) 0.89
CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol (1999) 0.88
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant (1997) 0.88
Leptomeningeal toxoplasmosis after allogeneic marrow transplantation. Case report and review of the literature. Am J Clin Oncol (1993) 0.88
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant (2000) 0.88
Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant (1999) 0.88